Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Dr Pollard’s work is focused on a form of kidney cancer for which no effective therapy exists once it metastasizes. By integrating analyses of these cancer cells and novel models he hopes to provide insights into altered cancer metabolism and a real, innovative route into the design of therapies for various cancers.

How do cancer cells produce their energy?

PP: All cells use glucose from the diet, and they convert this through a series of pathways to generate energy. Another requirement for cells to produce energy is oxygen. It has been known for quite some time that cancer cells require more glucose than normal cells and also more recently we found out they don't require as much oxygen. Cancer cells also have the ability to use alternative pathways to generate the energy. This is the main focus of our group - to try and elucidate these alternative mechanisms and how they may give cancer cells a growth survival.

What happens when there are defects in the cells pathways?

PP: Cells can use many alternative pathways to generate energy. Two important pathways are glycolysis and the Krebs cycle. Both of these are a series of reactions which produce substances called metabolites which aside from the role in energy production are important in cell maintenance. Our particular interest is focused on a Krebs cycle enzyme called fumarate hydratase. Defects in fumerate hydratase cause high levels of metabolite fumarate to accumulate and this can have a drastic effect on cell metabolism.

How is this linked with the onset of cancer?

PP: There is no direct evidence to date linking fumarate accumulation with cancer, however we and others have shown the accumulation of fumarate has a significant effect on the ability of the cell to undergo metabolism. At present we are trying to characterise these changes. Some of these involve conferring a survival advantage upon cells and of course this can be directly linked to the progression of cancer.

What are the most important lines of research that have developed over the last five to ten years?

PP: Cancer research has being rapidly evolving over the last century starting with the biochemistry era followed by the genomic era where we saw a lot of cancer associated genes - tumour suppressor genes and oncogenes - identified. Recently the last five to ten years has seen a vast increase in metabolic studies of cancer and understanding how cancer cells produce their energy and have survival advantages. This has been facilitated by increases in technology including sensitivity of mass spectrometry and also the ability to label specific metabolites within cells and track these metabolites.

Why does your line of research matter, why should we put money into it?

PP: Kidney cancer only accounts for around 3% of all cancers. The kidney cancer we are working on which is associated with the specific genetic defects of fumerate hydratase is a highly aggressive form of kidney cancer. Actually when these cancers metastasize, spread throughout the body to date there are no effective therapies. We are hoping that by analysing the metabolism of these cancers and trying to elucidate the energy produced in pathways that they require, we can help design targets for therapy.

How does your research fit into Translational Medicine within the Department?

PP: Recently we identified the novel biomarker which is sensitive and specific enough to be used in the clinical setting and this is specifically to identify cancers with their specific genetic defects in fumerate hydratase. We have also created numerous models so we can study metabolism in greater detail, and we are hoping that these models might be applicable to other metabolic diseases which include diabetes and obesity.

Patrick Pollard

Alternative metabolism in cancer cells

Cancer cells produce energy predominately by a high rate of glycolysis. It has been suggested that this change in metabolism is a fundamental cause of cancer. Dr Patrick Pollard aims to elucidate the alternative metabolic strategies used by cancer cells to proliferate, even under conditions of stress.

This podcast presents the research done by Dr Pollard whilst working in the Nuffield Department of Medicine.

More podcasts related to Ex-faculty podcasts

Raghib Ali: INDOX Cancer Research Network

INDOX is a collaboration between Oxford and twelve leading cancer centres in India. It aims to develop effective and affordable cancer treatments in low and middle income countries, to improve the early detection of cancer, and to reduce the incidence of cancer by establishing the population specific risk factors.

Richard Antrobus: Universal Flu Vaccine

A Universal Flu Vaccine would protect against a wide range of strains of the virus. Universal vaccines target the parts of the virus that stay relatively stable and are the same between different strains of flu. The ultimate goal is to produce a vaccine that will eventually replace the normal seasonal flu jab.

Colin Baigent: Lowering cholesterol in chronic kidney disease

The SHARP study involved almost 9,500 volunteers aged 40 or over with chronic kidney disease recruited from 380 hospitals in 18 countries. Volunteers were randomly allocated to take either cholesterol-lowering therapy with a tablet containing ezetimibe 10mg daily and simvastatin 20mg daily, or matching dummy "placebo" tablets for an average of 5 years.

Colin Baigent: Wider statin use saves lives

Prof Colin Baigent discusses how the benefits outweigh the hazards of Cholesterol-lowering drugs.

Paul Bowness: Spondyloarthritis

Spondyloarthritis describes a group of arthritic illnesses where there is inflammation of the joints of the lower back. Joints become painful and stiff, and inflammation ultimately fuses the spine. A better understanding of the role of various immune components might help us better prevent it and perhaps cure it.

Vincenzo Cerundolo: Cancer immunology

The development of therapeutic vaccines is more challenging. Current lines of research include the development of antibodies blocking inhibitory T cell signals, and the characterisation of adjuvants.

Hal Drakesmith: Iron and Infection

Pathogens can escape recognition by the immune system, but they require iron from their host to grow and spread. If iron availability is high, infection can progress more rapidly. Diverting iron away from invading microbes slows their growth, giving time for our immune mechanisms to clear the infection. Manipulating iron transport might lead to new strategies to combat infections.

Christian Eggeling: Nano-immunology

Super-resolution optical microscopy allows us to study immunological processes on the molecular level. We can get new insights into how our body reacts to viral or bacterial attacks. This has the potential to help us design new drugs and developing new ways of treating diseases.

Barbara Fielding: Metabolism of Fatty Acids

Obesity puts a huge strain on health care services in the UK, with 61% of people in England being overweight. By tracing fats containing heavy atoms from meals into the blood, her aim is to learn more about fat metabolism and target treatments for the complications associated with obesity and diabetes.

Alexander Finlayson: MedicineAfrica

This podcast presents the research done by Dr Alexander Finlayson whilst working in the Nuffield Department of Medicine. Dr Finlayson now works at the Nuffield Department of Population Health.

Translational Medicine

From Bench to Bedside

Ultimately, medical research must translate into improved treatments for patients. At the Nuffield Department of Medicine, our researchers collaborate to develop better health care, improved quality of life, and enhanced preventative measures for all patients. Our findings in the laboratory are translated into changes in clinical practice, from bench to bedside.